Overview

First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin

Status:
Active, not recruiting

Trial end date:
2022-07-31

Target enrollment:

Participant gender:

Summary

The research study is testing the investigational drug necitumumab (IMC-11F8) in the treatment of advanced non-small cell lung cancer. The aim of this study is to determine if necitumumab, given together with a standard chemotherapy combination consisting of cisplatin and gemcitabine will be more effective in improving participant disease than the standard chemotherapy combination alone.

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Collaborators:

ICON Clinical Research
Intertek
Laboratory Corporation of America
Medidata Solutions
Pacific Biomarkers
Parexel
PPD
Sysmex Inostics GmbH
Thermo Fisher Scientific
University of Colorado, Denver

Treatments:

Antibodies, Monoclonal
Cisplatin
Gemcitabine
Necitumumab